SDR16C6P: A Potential Drug Target and Biomarker for Short Chain Dehydrogenase/Reductase Family 16C

Target Name: SDR16C6P

NCBI ID: G442388

SDR16C6P

Other Name(s): short chain dehydrogenase/reductase family 16C member 6, pseudogene | Short chain dehydrogenase/reductase family 16C, member 6, pseudogene | SDR16C6

SDR16C6P: A Potential Drug Target and Biomarker for Short Chain Dehydrogenase/Reductase Family 16C

Introduction

Short chain dehydrogenase/reductase family 16C (SDR16C) is a gene family that encodes a diverse set of enzymes involved in the metabolism of polar molecules, including aromatic compounds, such as drugs, toxins, and environmental pollutants. One of the encoded proteins, SDR16C6P , has been identified as a potential drug target and biomarker for several reasons. This article will provide an overview of SDR16C6P, its function, and potential therapeutic applications.

Function and Structure

SDR16C6P is a member of the SDR16C gene family, which includes several related genes involved in the metabolism of aromatic compounds. The SDR16C6P gene encodes a protein with 61 amino acid residues, which is 11% identical to the protein encoded by the human gene SDR16C6. SDR16C6P is a single-stranded protein that contains 4 unique amino acids at its C-terminus, which may be involved in its stability or interactions with other proteins.

SDR16C6P is involved in the metabolism of various aromatic compounds, including drugs, toxins, and environmental pollutants. Its primary function is to convert aromatic rings into more polar molecules, such as thiol compounds. This conversion is critical for the detoxification and excretion of these molecules, which are often toxic or harmful to human health.

SDR16C6P is a potent enzyme that can catalyze the conversion of various aromatic rings into thiol compounds. For example, it can convert the aromatic ring of the drug indomethacin into a more polar molecule, such as 2-methyindomethacin. This transformation is critical for the efficacy of indomethacin as an anti-inflammatory drug. Similarly, SDR16C6P can also convert the aromatic ring of the environmental pollutant 2,4,6-trichloro-2,4-dinitrophenol (TDC) into a more polar molecule, such as 2,4, 6-trichloro-2,4-dinitrophenol-mercapto compound, which can be easily detected and quantified in the environment.

Potential Therapeutic Applications

SDR16C6P has several potential therapeutic applications, including the development of new anti-inflammatory drugs, toxins, and environmental pollutants. Its ability to convert aromatic rings into more polar molecules makes it an attractive target for the development of new drugs that can selectively target aromatic compounds.

One of the potential therapeutic applications of SDR16C6P is the development of new anti-inflammatory drugs. Indomethacin, which is commonly used to treat inflammatory conditions such as rheumatoid arthritis and colitis, is an example of an aromatic compound that can be converted into a more polar molecule by SDR16C6P. The development of new anti-inflammatory drugs that target SDR16C6P may provide a more targeted and effective treatment for these conditions.

Another therapeutic potential application of SDR16C6P is the development of new toxins that can selectively target specific organs and tissues. For example, SDR16C6P can be used to convert the aromatic ring of the environmental pollutant TDC into a more polar molecule, which can be easily detected and quantified in the environment. The development of new toxins that target SDR16C6P may provide a more targeted and effective treatment for environmental

Protein Name: Short Chain Dehydrogenase/reductase Family 16C Member 6, Pseudogene

The "SDR16C6P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SDR16C6P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets